Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
HK2 inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "HK2 inhibitor" in MCE Product Catalog:
52
Target:
Research Areas:
Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
52
52 Publications Verification
Cat. No.: HY-15947A
CAS No.: 2070009-58-2
Synonyms: GDC-0994 hydrochloride
Target:
Research Areas:
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
4
4 Cited Publications
Cat. No.: HY-N2445
CAS No.: 37308-75-1
3
3 Cited Publications
Cat. No.: HY-N4185
CAS No.: 61153-77-3
2
2 Cited Publications
Target:
Research Areas:
PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
1
1 Cited Publications
Synonyms: Cycloartenol ferulate; Cycloartenol ferulic acid ester
Category:
Cardiovascular Disease Cercis chinensis Bunge Metabolic Disease Plants Compositae other families Flavonoids Flavonones Phenols Polyphenols Disease Research Fields
Target:
Cat. No.: HY-175035
CAS No.: 3114833-48-3
Target:
Research Areas:
HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer .
Cat. No.: HY-168717
CAS No.: 3056278-80-6
Research Areas:
HK2-IN-2 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. HK2-IN-2 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .
Target:
Research Areas:
p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4].
non-alcoholic fatty liver disease .
Cat. No.: HY-182243
CAS No.: 2748366-80-3
Target:
Research Areas:
HK2-IN-4 is a selective hexokinase 2 (HK2) inhibitor with an IC50 value of 0.79 μM and a Kd value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 (VDAC1). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis (apoptosis) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer .
Cat. No.: HY-156368
CAS No.: 2304617-58-9
Target:
Research Areas:
RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .
Cat. No.: HY-179378
CAS No.: 2968523-32-0
Research Areas:
XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM). XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease .
Cat. No.: HY-180805
CAS No.: 2679261-30-2
Target:
Research Areas:
HK2-IN-3 is a selective HK2 inhibitor with a human IC50 of 0.0564 μM (56.4 nM). HK2-IN-3 induces mitophagy in oral squamous cell carcinoma cells. HK2-IN-3 exerts anti-cancer activity in oral squamous cell carcinoma cells. HK2-IN-3 can be used for the research of oral squamous cell carcinoma .
Cat. No.: HY-183809
CAS No.: 3124329-46-7
Target:
Research Areas:
ZSW is a hexokinase 2 (HK2) inhibitor with human HK2 IC50 of 0.48 μM, human HK2 Ka of 252.00 μM, and selectivity over HK3 and GCK. ZSW binds directly to HK2, inhibits its enzymatic activity, modulates macrophage phenotypes through glycolysis inhibition, and inhibits NF-κB nuclear translocation by preventing IκBα phosphorylation and degradation. ZSW alleviates inflammatory bowel disease (IBD) and improves the intestinal inflammatory state of IBD mice. ZSW can be used for the research of inflammatory bowel disease .
Cat. No.: HY-15947B
CAS No.: 1817728-45-2
Synonyms: GDC-0994 benzenesulfonate
Target:
Research Areas:
Ravoxertinib benzenesulfonate (GDC-0994 benzenesulfonate) is an orally active ERK1/2 inhibitor. Ravoxertinib benzenesulfonate inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib benzenesulfonate decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib benzenesulfonate can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
Cat. No.: HY-15947G
CAS No.: 1453848-26-4
Synonyms: GDC-0994 (GMP)
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
